computer-generated block randomization schedule (Glaxo Smith)
90
Structured Review
Glaxo Smith
computer-generated block randomization schedule
Computer Generated Block Randomization Schedule, supplied by Glaxo Smith, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/computer-generated+block+randomization+schedule/computer+generated+randomization+schedule/pm22103635-89-22-29
Average 90 stars, based on 1 article reviews
Computer Generated Block Randomization Schedule, supplied by Glaxo Smith, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/computer-generated+block+randomization+schedule/computer+generated+randomization+schedule/pm22103635-89-22-29
Average 90 stars, based on 1 article reviews
computer-generated block randomization schedule - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Sequencing:Article Title: Drugs for the acute treatment of migraine in children and adolescents Article Snippet: .. Random sequence generation (selection bias) , Low risk , Quote: "randomized in a 1:1:1 ratio (in blocks of six) to one of three treatment groups"; "computer‐generated Article Title: Vaccines for preventing rotavirus diarrhoea: vaccines in use Article Snippet: Seroconversion: appearance of anti-rotavirus IgA antibody concentration ≥ 20 U/mL in participants seronegative for rotavirus before vaccination (review includes data from 1 to 2 months after dose 2) Immunization status Concomitant vaccines included 7 valent pneumococcal polysaccharide conjugate vaccine (Prevenar) and meningococcal group c conjugate vaccine (Meningitec); Hepatitis B vaccine, diphtheria-tetanusacellular pertussis, polio virus, and H. influenzae type b vaccines were co-administered Location 98 centres in 6 European countries (Czech Republic, Finland, France, Germany, Italy, and Spain) WHO mortality stratum A Notes Date: 12 February 2007 to 08 August 2007 Source of funding: funded by GlaxoSmithKline Biologicals Other: vaccination postponed if baby either had a temperature of ≥ 37.5 °C (axillary) or of 38.0 °C (rectal) or had gastroenteritis within 7 days before planned vaccination Study aim: "to assess the efficacy and safety of HRV [RV1] vaccine during the 3rd year of age in subjects primed with a 2-dose schedule in study 102247, with the first dose administered at the age of 6 to 14 weeks" .. Bias Authors' judgement Support for judgement Random sequence generation (selection bias) Low risk Quote: "GSK Biologicals provided Article Title: Tafenoquine for preventing relapse in people with Plasmodium vivax malaria Article Snippet: .. Random sequence generation (selection bias) , Low risk , Quote: "With the use of a computer‐generated Selection:Article Title: Drugs for the acute treatment of migraine in children and adolescents Article Snippet: .. Random sequence generation (selection bias) , Low risk , Quote: "randomized in a 1:1:1 ratio (in blocks of six) to one of three treatment groups"; "computer‐generated Article Title: Vaccines for preventing rotavirus diarrhoea: vaccines in use Article Snippet: Seroconversion: appearance of anti-rotavirus IgA antibody concentration ≥ 20 U/mL in participants seronegative for rotavirus before vaccination (review includes data from 1 to 2 months after dose 2) Immunization status Concomitant vaccines included 7 valent pneumococcal polysaccharide conjugate vaccine (Prevenar) and meningococcal group c conjugate vaccine (Meningitec); Hepatitis B vaccine, diphtheria-tetanusacellular pertussis, polio virus, and H. influenzae type b vaccines were co-administered Location 98 centres in 6 European countries (Czech Republic, Finland, France, Germany, Italy, and Spain) WHO mortality stratum A Notes Date: 12 February 2007 to 08 August 2007 Source of funding: funded by GlaxoSmithKline Biologicals Other: vaccination postponed if baby either had a temperature of ≥ 37.5 °C (axillary) or of 38.0 °C (rectal) or had gastroenteritis within 7 days before planned vaccination Study aim: "to assess the efficacy and safety of HRV [RV1] vaccine during the 3rd year of age in subjects primed with a 2-dose schedule in study 102247, with the first dose administered at the age of 6 to 14 weeks" .. Bias Authors' judgement Support for judgement Random sequence generation (selection bias) Low risk Quote: "GSK Biologicals provided Article Title: Tafenoquine for preventing relapse in people with Plasmodium vivax malaria Article Snippet: .. Random sequence generation (selection bias) , Low risk , Quote: "With the use of a computer‐generated other:Article Title: A phase 2a, randomized, crossover trial of gabapentin enacarbil for the treatment of postherpetic neuralgia in gabapentin inadequate responders. Article Snippet: The Article Title: Single-Dose Tafenoquine to Prevent Relapse ofPlasmodium vivaxMalaria Article Snippet: With the use of a computer-generated randomization schedule provided by Article Title: Tocolytics for delaying preterm birth: a network meta-analysis (0924) Article Snippet: Funded by Article Title: Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial Article Snippet: Patients were randomised centrally across all sites in accordance with a |